Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyAmanda Psyrri, Tanguy Y. Seiwert, А. А. Карпенко et al.|Annals of Oncology|2022Cited by 144
Macrophage secretory IL-1β promotes docetaxel resistance in head and neck squamous carcinoma via SOD2/CAT-ICAM1 signalingChing-Yun Hsieh, Wei‐Chao Chang|JCI Insight|2022Cited by 47
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and NeckRobert I. Haddad, Deborah Jean Lee Wong, Jérôme Fayette et al.|JAMA|2025Cited by 42
Taxanes in the Treatment of Head and Neck Squamous Cell CarcinomaChing-Yun Hsieh, Wei‐Chao Chang|Biomedicines|2023Cited by 10
Taxanes in the Treatment of Head and Neck Squamous Cell CarcinomaChing-Yun Hsieh, Wei‐Chao Chang|Preprints.org|2023Cited by 4